566
Views
27
CrossRef citations to date
0
Altmetric
Reviews

Intravenous immunoglobulin as treatment for myasthenia gravis: current evidence and outcomes

, , , &

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Shuhui Wang, Iva Breskovska, Shreya Gandhy, Anna Rostedt Punga, Jeffery T. Guptill & Henry J. Kaminski. (2018) Advances in autoimmune myasthenia gravis management. Expert Review of Neurotherapeutics 18:7, pages 573-588.
Read now

Articles from other publishers (26)

David S. Younger. 2023. Motor System Disorders, Part I: Normal Physiology and Function and Neuromuscular Disorders. Motor System Disorders, Part I: Normal Physiology and Function and Neuromuscular Disorders 707 777 .
David S. Younger. 2023. Motor System Disorders, Part I: Normal Physiology and Function and Neuromuscular Disorders. Motor System Disorders, Part I: Normal Physiology and Function and Neuromuscular Disorders 315 358 .
Cristina Segú-Vergés, Silvia Caño, Elisabeth Calderón-Gómez, Helena Bartra, Teresa Sardon, Srini Kaveri & José Terencio. (2022) Systems biology and artificial intelligence analysis highlights the pleiotropic effect of IVIg therapy in autoimmune diseases with a predominant role on B cells and complement system. Frontiers in Immunology 13.
Crossref
Marina Mané-Damas, Peter C. Molenaar, Peter Ulrichts, Florit Marcuse, Marc H. De Baets, Pilar Martinez-Martinez & Mario Losen. (2022) Novel treatment strategies for acetylcholine receptor antibody-positive myasthenia gravis and related disorders. Autoimmunity Reviews 21:7, pages 103104.
Crossref
Seung Ah Kang, Megan Sweeney & Raghav Govindarajan. (2022) Academic and Employment Status in Patients With Generalized Myasthenia Gravis Treated With Eculizumab: A Case Series. Journal of Clinical Neuromuscular Disease 23:4, pages 210-218.
Crossref
Eric M. Tichy, Barbara Prosser & Drew Doyle. (2020) Expanding the Role of the Pharmacist: Immunoglobulin Therapy and Disease Management in Neuromuscular Disorders. Journal of Pharmacy Practice 35:1, pages 106-119.
Crossref
Shin J. Oh. 2022. Neuromuscular Disorders. Neuromuscular Disorders 446 491 .
Swathi Beladakere Ramaswamy, Shivangi Singh, Sara Hooshmand, Cho Junsang, Megan Sweeney & Raghav Govindarajan. (2021) Current and Upcoming Treatment Modalities in Myasthenia Gravis. Journal of Clinical Neuromuscular Disease 23:2, pages 75-99.
Crossref
Jie Lin, Binbin Xue, Ruofan Zhu, Juyuan Pan, Jia Li, Yan Lin, Xiang Li & Junhui Xia. (2021) Intravenous immunoglobulin as the rescue treatment in NMOSD patients. Neurological Sciences 42:9, pages 3857-3863.
Crossref
Shengyao Su, Qing Liu, Xueping Zhang, Xinmei Wen, Lin Lei, Faxiu Shen, Zhirong Fan, Jianying Duo, Yan Lu, Li Di, Min Wang, Hai Chen, Wenjia Zhu, Min Xu, Suobin Wang & Yuwei Da. (2021) VNTR2/VNTR3 genotype in the FCGRT gene is associated with reduced effectiveness of intravenous immunoglobulin in patients with myasthenia gravis . Therapeutic Advances in Neurological Disorders 14, pages 175628642098674.
Crossref
Peter Manu, Liliana M. Rogozea & Corina Roman-Filip. (2021) Pharmacological Management of Myasthenia Gravis: A Century of Expert Opinions in Cecil Textbook of Medicine. American Journal of Therapeutics 28:6, pages e631-e637.
Crossref
Gabriela Riemekasten, Frank Petersen & Harald Heidecke. (2020) What Makes Antibodies Against G Protein-Coupled Receptors so Special? A Novel Concept to Understand Chronic Diseases. Frontiers in Immunology 11.
Crossref
Ali Aamer Habib, Ghazaleh Ahmadi Jazi & Tahseen Mozaffar. (2020) Update on immune‐mediated therapies for myasthenia gravis. Muscle & Nerve 62:5, pages 579-592.
Crossref
Laura Díez-Porras, Christian Homedes, Maria Antonia Alberti, Valentina Vélez-Santamaría & Carlos Casasnovas. (2020) Intravenous immunoglobulins may prevent prednisone-exacerbation in myasthenia gravis. Scientific Reports 10:1.
Crossref
Deepak Menon, Carolina Barnett & Vera Bril. (2020) Novel Treatments in Myasthenia Gravis. Frontiers in Neurology 11.
Crossref
Wenhua Xu, Mingshan Ren, Swagata Ghosh, Kai Qian, Zhaofeng Luo, Aimei Zhang, Cuiping Zhang & Jiajun Cui. (2020) Defects of CTLA-4 Are Associated with Regulatory T Cells in Myasthenia Gravis Implicated by Intravenous Immunoglobulin Therapy. Mediators of Inflammation 2020, pages 1-13.
Crossref
Bonnie J. B. Lewis, Jade Ville, Megan Blacquiere, Selena Cen, Rolf Spirig, Adrian W. Zuercher, Fabian Käsermann & Donald R. Branch. (2019) Using the K/BxN mouse model of endogenous, chronic, rheumatoid arthritis for the evaluation of potential immunoglobulin-based therapeutic agents, including IVIg and Fc-μTP-L309C, a recombinant IgG1 Fc hexamer. BMC Immunology 20:1.
Crossref
Waqar Waheed, Gretchen A. Ayer, Cindy L. Jadoo, Gary J. Badger, Marwa Aboukhatwa, Thomas H. BrannaganIIIIII & Rup Tandan. (2019) Safety of intravenous immune globulin in an outpatient setting for patients with neuromuscular disease. Muscle & Nerve 60:5, pages 528-537.
Crossref
Jonnathan Patiño, Diana Garzón, Tatiana Pacheco & Aldair Chaar. (2019) Recaída de miastenia gravis: ¿inmunoglobulina intravenosa como estrategia inicial en pacientes refractarios al tratamiento convencional?. Acta Colombiana de Cuidado Intensivo 19:2, pages 106-111.
Crossref
Adrian W. Zuercher, Mel Berger, Reinhard Bolli, Cédric Vonarburg, Martin Spycher, Amgad Shebl, Rolf Spirig, Christoph Kempf, Fabian Käsermann & Sylvia Miescher. 2019. Nijkamp and Parnham's Principles of Immunopharmacology. Nijkamp and Parnham's Principles of Immunopharmacology 327 368 .
Asaf Shemer, Shaye Kivity & Yehuda Shoenfeld. (2017) Clinical indications for intravenous immunoglobulin utilization in a tertiary medical center: a 9‐year retrospective study. Transfusion 58:2, pages 430-438.
Crossref
Paul Imbach. 2018. Antibody Therapy. Antibody Therapy 35 60 .
Aidan A. Levine, Todd D. Levine, Kathie Clarke & David Saperstein. (2017) Renal and hematologic side effects of long-term intravenous immunoglobulin therapy in patients with neurologic disorders. Muscle & Nerve 56:6, pages 1173-1176.
Crossref
P. R. Bourque, C. E. Pringle, W. Cameron, J. Cowan & J. Warman Chardon. (2016) Subcutaneous Immunoglobulin Therapy in the Chronic Management of Myasthenia Gravis: A Retrospective Cohort Study. PLOS ONE 11:8, pages e0159993.
Crossref
Jiří Piťha. (2016) Cardiac function in hypertensive patients with metabolic syndrome and microalbuminuria. Neurologie pro praxi 17:3, pages 95-99.
Crossref
Inga Koneczny, Pilar Martinez Martinez & Marc De Baets. 2016. Encyclopedia of Immunobiology. Encyclopedia of Immunobiology 168 179 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.